Table 2 Clinically available photosensitizers and anticipated treatment times6,9,21.
From: An Implantable Ultrasonically-Powered Micro-Light-Source (µLight) for Photodynamic Therapy
Platform | Substance | Wavelength (nm) | Concentration (mg/kg) | Light Energy (J/cm2) | Treatment time (hours) | Target organ | ||
|---|---|---|---|---|---|---|---|---|
µLight222 red | µLight242 red | µLight242 blue | ||||||
Porphyrin | HpD | 408, 630 | 0.8–2.0 | 200–300 | 1157.4–1736.1 | 50.5–75.8 | 9.1–13.7 | Lung, Head, Neck, Bladder |
Porphyrin | ALA | 410, 635 | 100 umol/L | 3–4 | 34.7–138.9 | 1.5–6.1 | 0.13–13.7 | Head, Neck, Bladder, Prostate |
Chlorine | Temoporfin | 652 | 0.1–0.2 | 20 | 115.7 | 5.1 | 0.9 | Lip, Oral, Lung, Stomach, Pancreatic |
Chlorine | Talaporfin sodium | 408, 664 | >2.5 | 100 | 578.7 | 25.3 | 4.3 | Head, Neck |
Chlorine | HPPH | 408, 665 | 2.5–6 | 44.4–133.2 | 256.9–770.8 | 11.2–25.3 | 1.9–5.7 | Lung |
Padoporfin | Phthalocyanine | 670–763 | — | 100 | 578.7 | 25.3 | 4.3 | Lip, Pharynx, Larynx, Tongue |
Porphyrin | Verteporfin | 690 | — | 100 | 578.7 | 25.3 | 4.3 | Eye |
Texaohyrins | Lutexaphyrin | 732 | 0.5–2 | 2.5–150 | — | — | — | Breast |
